Provided by Tiger Trade Technology Pte. Ltd.

Invivyd, Inc.

0.7898
-0.0075-0.94%
Volume:129.05K
Turnover:100.92K
Market Cap:232.99M
PE:-2.17
High:0.7993
Open:0.7822
Low:0.7703
Close:0.7973
52wk High:3.07
52wk Low:0.5277
Shares:295.00M
Float Shares:208.00M
Volume Ratio:0.93
T/O Rate:0.06%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.3641
EPS(LYR):-0.3048
ROE:-95.89%
ROA:-45.67%
PB:1.29
PE(LYR):-2.59

Loading ...

Invivyd Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

THOMSON REUTERS
·
Aug 04

Invivyd Gets NASDAQ Notice After Shares Trade Below $1 Minimum Bid Price

Reuters
·
Jul 25

Analysts Conflicted on These Healthcare Names: Cipher Pharmaceuticals (OtherCPHRF), Invivyd (IVVD) and Merck & Company (MRK)

TIPRANKS
·
Jul 09

Invivyd Price Target Maintained with a $10.00/share by BTIG

Dow Jones
·
Jul 07

FDA to End Emergency Use Authorization for Invivyd's Covid-19 Prevention Shot

Dow Jones
·
Jul 06

Invivyd announces notice of termination for Pemgarda Emergency Use Authorization

TIPRANKS
·
Jul 06

Invivyd Says FDA Sets June 29, 2027 Termination Date for Pemgarda EUA

Reuters
·
Jul 06

Invivyd - in Dialogue with FDA on Next Steps for Pemgarda

THOMSON REUTERS
·
Jul 06

Invivyd Announces Receipt of Twelve Months’ Advanced Notice of Emergency Use Authorization (eua) Termination for Pemgarda® and Provides an Update on Next Steps with the U.S. FDA

THOMSON REUTERS
·
Jul 06

Invivyd - FDA to Terminate Pemgarda Eua Effective June 29, 2027

THOMSON REUTERS
·
Jul 06

Novabridge Biosciences Appoints DR. Srishti Gupta as Chief Executive Officer

THOMSON REUTERS
·
Jun 29

Invivyd posts CANOPY older-adult subgroup analysis presentation on pemivibart for COVID-19 prevention

Reuters
·
Jun 17

Invivyd completes enrollment of LIBERTY clinical trial

TIPRANKS
·
Jun 16

Invivyd's Late-Stage Trial of Covid Vaccine Alternative Completes Enrollment; Shares Rise Pre-Bell

MT Newswires Live
·
Jun 16

Invivyd - to Report Liberty Study Results in Q3 2026

THOMSON REUTERS
·
Jun 16

Invivyd Announces Completion of Enrollment in Phase 3 Liberty Trial Evaluating Vyd2311 Antibody Versus Mrna Covid-19 Vaccine

THOMSON REUTERS
·
Jun 16

Invivyd Price Target Maintained With a $10.00/Share by HC Wainwright & Co.

Dow Jones
·
Jun 15

Invivyd Price Target Maintained With a $10.00/Share by BTIG

Dow Jones
·
Jun 10

BRIEF-Invivyd - Expects Liberty Trial Topline Data In Q3 2026

Reuters
·
Jun 09

Invivyd doses first participants in Phase 3 LIBERTY trial of VYD2311 vs mRNA COVID vaccine

Reuters
·
Jun 09